Stock info Evotec | Filter  Basic-Info

Evotec

The past year was a profitable year Evotec investors

The stock gained over the past 12 months at around 66 percent. Evotec ' stock rose the past 5 years at around 187 percent. Evotec 's revenues between 2011 and 2015 were very volatile and moved between 87,27 million euros and 127,68 million euros. Evotec 's net results between 2011 and 2015 were far from constant and moved between 6,65 million euros and 16,52 million euros.

Evotec has her headquarter located in Hamburg. The core activities of Evotec are in the pharmaceutical sector. Dr Werner Lanthaler is the company' CEO. Evotec ' CFO is Colin Bond. The past 10 years the (international) industry gained at around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-2016) there is a minus of 75 percent.

Evotec didn't pay out any dividends (in the past 5 years).

At the end of 2015 Evotec employed at around 689 people.

Evotec financed with relatively low debt

At the end of 2015 the German company had a balance sheet of around 288,54 million euros. At the end of 2015 the total debt positon equaled 103,04 million euros. This is around 35,71 percent of the total balance sheet. The German company's price/earnings-ratio was 23. So the market valued the stock at 23 times the 2015' earnings per share. Many analysts say that based on her price/earnings-ratio and dividend yield the German stock can be seen as a value stock.

The pharmaceutical company's market capitalization (the number of shares outstanding times the market value) equaled around 535,93 million euros. At the end of 2015 the German company had around 131,68 million stocks listed.

All Evotec 's annual reports can be found here. More information about Evotec can be found it's website. .